You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 20209809
Dec 20202405
Jan 20211703
Feb 20211504
Mar 20214006
Apr 202130010
May 2021608
Jun 2021003
Jul 2021003
Aug 2021006
Sep 2021004
Oct 202126024
Nov 202124016
Dec 20211403
Jan 20221401
Feb 20222001
Mar 20222200
Apr 20222403
May 20222200
Jun 20221403
Jul 20222604
Aug 20222201
Sep 20222204
Oct 20222202
Nov 20221602
Dec 20223201
Jan 20231001
Feb 20231601
Mar 20231605
Apr 20231002
May 20231803
Jun 2023802
Jul 2023602
Aug 20232802
Sep 2023200
Oct 20233203
Nov 20231401
Dec 20233800
Jan 20241801
Feb 20242000
Mar 20242800
Apr 20242400
May 20241403
Jun 20242600
Jul 20242002
Aug 2024601
Sep 20241602
Oct 20241205
Nov 20242001
Dec 20241002
Jan 20251406
Feb 2025001
Mar 2025001
Apr 2025002
May 2025006
Jun 2025002
Total9760183